Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy

Summary

Thrombocytopenia represents one of the main toxicities of concurrent chemoradiotherapy, which may necessitate chemotherapy dose reductions, dose delays, or discontinuation, and even compromise survival. Hetrombopag, a thrombopoietin receptor agonist, has shown efficacy and safety in patients with chemotherapy-induced thrombocytopenia. However, the efficacy of hetrombopag in patients who received concurrent chemoradiotherapy is not clear yet. This study aimed to evaluate the efficacy and safety of hetrombopag in this patient population.

Timeline

Start

2022-05-10

Primary completion

2025-05-30

Completion

2025-07-30

Drugs

Indications